HMB-45 (gp103) and MART-1 expression within giant cells in an atypical fibroxanthoma: A case report

Journal of Cutaneous Pathology

Volumn 31, Issue 3, 2004, Pages 284-286

  Smith Zagone, Megan J ^a   Prieto, Victor G ^a   Hayes, Ruth A ^b   Timperman Jr , Walter W ^c   Diwan, A Hafeez ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Wilmington Surgical Associates Inc   (United States)

^c Clinton Memorial Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD68 ANTIGEN; GLYCOPROTEIN; GLYCOPROTEIN GP 103; KERATIN; MELAN A; PROTEIN S 100; UNCLASSIFIED DRUG;

ADULT; ANAMNESIS; ANTIGEN EXPRESSION; ARTICLE; CASE REPORT; CLINICAL FEATURE; CYTOPLASM; FEMALE; FIBROXANTHOMA; GIANT CELL; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; MICROSCOPY; MULTINUCLEAR CELL; PROTEIN EXPRESSION; SCALP; SKIN DEFECT; SKIN SURGERY; SPINDLE CELL;

ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; FEMALE; GIANT CELLS; HISTIOCYTOMA, BENIGN FIBROUS; HUMANS; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; SCALP; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 1242315437     PISSN: 03036987     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0303-6987.2004.00173.x     Document Type: Article

References (21)

1. Fretzin DF, Helwig EB. Atypical fibroxanthoma of the skin. A clinicopathologic study of 140 cases. Cancer 1973; 31: 1541.
2. Weedon D. Skin pathology. London: Churchill Livingstone, 2002; 936.
3. Wick MR, Fitzgibbon J, Swanson PE. Cutaneous sarcomas and sarcomatoid neoplasms of the skin. Semin Diagn Pathol 1993; 10: 148.
4. Longacre TA, Smoller BR, Rouse RV. Atypical fibroxanthoma. Multiple immunohistologic profiles. Am J Surg Pathol 1993; 17: 1199.
5. Winkelmann RK, Peters MS. Atypical fibroxanthoma. A study with antibody to S-100 protein. Arch Dermatol 1985; 121: 753.
6. Ricci A Jr., Cartun RW, Zakowski MF. Atypical fibroxanthoma. A study of 14 cases emphasizing the presence of Langerhans' histiocytes with implications for differential diagnosis by antibody panels. Am J Surg Pathol 1988; 12: 591.
7. Silvis NG, Swanson PE, Manivel JC, Kaye VN, Wick MR. Spindle-cell and pleomorphic neoplasms of the skin. A clinicopathologic and immunohistochemical study of 30 cases, with emphasis on "atypical fibroxanthomas". Am J Dermatopathol 1988; 10: 9.
8. Ma CK, Zarbo RJ, Gown AM. Immunohistochemical characterization of atypical fibroxanthoma and dermatofibrosarcoma protuberans. Am J Clin Pathol 1992; 97: 478.
9. Dabbs DJ (ed). Diagnostic immunohistochemistry. Philadelphia: Churchill Livingstone, 2002; 147.
10. Yaziji H, Gown AM. Immunohistochemical markers of melanocytic tumors. Int J Surg Pathol 2003; 11: 11.
11. Clarkson KS, Sturdgess IC, Molyneux AJ. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A). J Clin Pathol 2001; 54: 196.
12. Adema GJ, deBoer AJ, Vogel AM, et al. Molecular characterization of the melanocyte lineage-specific antigen gp100. J Biol Chem 1994; 269: 20126.
13. Adema GJ, Bakker AB, deBoer J, et al. PMe117 is recognized by monoclonal antibodies NKI-beteb, HMB-45, HMB-50, and by anti-melanoma cytotoxic T-cells. Br J Cancer 1996; 73: 1044.
14. Smoller B. Immunohistochemistry in the diagnosis of melanocytic neoplasms. Pathol State Art Rev 1994; 2: 371.
15. Pea M, Bonetti F, Zamboni G, et al. Melanocyte-marker HMB-45 is regularly expressed in angiomyolipoma of the kidney. Pathology 1991; 23: 185.
16. Orosz Z. Melan-A/Mart-1 expression in various melanocytic lesions and in non-melanocytic soft tissue tumors. Histopathology 1999; 34: 517.
17. Busam KJ, Iversen K, Coplan KA, et al. Immunoreactivity for A103, an antibody to Melan-A (MART-1), in adrenocortical and other steroid tumors. Am J Surg Pathol 1998; 22: 57.
18. Kanitakis J, Jermier C, Chouvet B, et al. Reactivity of HMB45 monoclonal antibody with sweat gland tumours of the skin. Acta Derm Venereol 1991; 71: 426.
19. Bonetti F, Colombari R, Manfrin E, et al. Breast carcinoma positive for the melanoma marker (HMB45). HMB45 immunoreactivity in normal and neoplastic breast. Am J Clin Pathol 1989; 92: 91.
20. Barr RJ, Wuerker RB, Graham JH. Ultrastructure of atypical fibroxanthoma. Cancer 1977; 40: 736.
21. Trejo O, Reed JA, Prieto VG. Atypical cells in human cutaneous re-excision scars for melanoma express p75NGFR, CD56/N-CAM and GAP-43: evidence of early Schwann cell differentiation. J Cutan Pathol 2002; 29: 397.